“With the formation of Enterprise Singapore, our role is to grow stronger Singapore enterprises. Building on the foundation of the two previous organizations, we now have increased and improved resources to be more effective on both the domestic and international fronts.”
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.